Company and Stock Identity

How Iterative Health Connects to the Public Market

Company structure
Private company
Market access
No current public listing was verified.
Research focus
The group's test fits oddly here, because the product being sold is trial enrollment rather than a drug pipeline. Ask how much of the speed comes from the AI reading images and how much from owning the sites and staffing them, since those are different businesses with different margins. Six clearances sit in this site's FDA records under the names Iterative Health and Iterative Scopes, and whether those are the same company under an old name has not been confirmed, so only the Iterative Health records are linked on this profile.

Iterative Health announced a 77 million dollar Series C on 30 April 2026, led by Intrepid Growth Partners and GV with EDBI, a family office and existing investors Insight Partners and Obvious Ventures taking part. The company has also been buying research sites, announcing the acquisition of cardiology sites from NextStage Clinical Research on 14 May 2026. No change of control was announced. Checked on 2026-10-10.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Iterative Health ... Company source

Iterative Health raises 77 million dollars to put trial sites in community clinics

Iterative Health said on 30 April 2026 that it closed a 77 million dollar Series C led by Intrepid Growth Partners and GV, with new investors EDBI and a family office joining existing investors including Insight Partners and Obvious Ventures. The company describes itself as a healthcare technology and services company accelerating clinical research by combining centralised operations, expert staffing, its own AI technology and trial expertise into a multispecialty research network, and says the money funds expansion into cardiology and obesity beyond gastroenterology and hepatology. It reports site activation twice as fast, cutting startup timelines by up to three months, and enrollment rates three times higher, averaging more than two inflammatory bowel disease patients randomised every business day, and notes that nearly 90 percent of United States trials miss enrollment targets on time. Its AI product is named SKOUT.

Why it matters: The interesting shift is that this company started as endoscopy AI and is now a research site network that happens to own AI, and the funding is explicitly for buying into new therapy areas. For a sponsor that is a real option, because a network with its own staff can be held to an activation date in a way a loose group of sites cannot. It also means the AI claim and the operational claim need separating: three times enrollment could come from the algorithm finding patients or from paying coordinators to work harder, and the announcement does not split them. Two patients randomised a business day is a useful, checkable figure in a disease area where one a week is common.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: The careers page names clinical research and operations roles far more than engineering ones, including clinical research coordinator, director of clinical operations, senior clinical data analyst, senior clinical learning specialist and director of life sciences. Its only listed address is in Cambridge, Massachusetts, and openings sit on an outside job board.

Qualification signal: The hiring pattern says this is a clinical research organisation that owns AI rather than an AI company that runs trials. Trial site operations and coordinator experience is the transferable skill here; model building is a smaller part of the team than the AI story suggests.

Check current roles at Iterative Health. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Pharmaceutical R&D, biotechnology leadership, translational science, business development, and investors
Primary use case
Identify targets, design molecules, prioritize experiments, and connect biomedical data to research decisions
Typical deployment
Ranges from software and data partnerships to platform collaborations and internally owned drug pipelines

Evidence questions

  • Which results are prospective, reproduced, and tied to a clinical or experimental endpoint?
  • How many programs are AI-originated, AI-assisted, partnered, or internally owned?
  • What has advanced beyond target identification and preclinical reporting?

Regulatory and workflow questions

  • Which entity owns development, validation, and regulatory responsibility for each program?
  • How are model-generated hypotheses reviewed before experimental or clinical use?
  • What claims are about research productivity versus a regulated product?

Data and contract questions

  • Who owns generated molecules, targets, models, and derived data?
  • Which proprietary datasets create defensibility and which are licensed?
  • Can a partner reproduce outputs and export project data after the collaboration?

Evidence and Regulation

FDA Clearances on Record

Iterative Health appears on 2 cleared products in the federal 510(k) record, across 1 device type.

A clearance means the FDA agreed the product is close enough to something already on the market to be sold for that use. It is not a finding that the product helps patients, and it is not a ranking against anything else on this page. A company is linked to an FDA clearance only when the 510(k) applicant name on the government record is confirmed by hand to be that same company, including former corporate names. Name similarity alone is never enough, and rejected matches are listed below with the reason.

First-Hand Sources